Antibe Therapeutics, Inc. (ATBPF: OTCQX International) | Antibe Therapeutics Reports Q2 2017 Interim Financial and Operating Results


Antibe Therapeutics Reports Q2 2017 Interim Financial and Operating Results

Nov 29, 2016

OTC Disclosure News Service

Antibe Therapeutics Inc. (“Antibe”) (TSXV:ATE) (OTCQX:ATBPF) filed its
financial and operating results on Tuesday, November 29 for the fiscal
quarter ended September 30, 2016. The Corporation’s unaudited fiscal Q2
2017 interim consolidated financial statements and MDA are available on

“The clinical development of ATB-346 continues to be the top priority
for our executive team as we prepare to initiate a double-blind,
placebo-controlled, phase 2 dose-ranging clinical study for
osteoarthritis in the new year,” said Dan Legault, Antibe’s CEO. “In
addition, Citagenix has been executing upon its U.S. expansion strategy
and has taken steps to concentrate its focus on dental regenerative
medicine. In particular, Citagenix has decided to slowly withdraw from
the orthopedic market and has repositioned its surgical instrument line
to be more complementary to its dental regenerative business. The launch
of its growth initiative in the USA last month is a significant
milestone for Citagenix’s global expansion strategy and we expect it to
deliver a positive contribution to profitability within a few quarters.”

Q2 2017 Highlights

  • Successfully completed initial phase 2 clinical trial of ATB-346 in
    osteoarthritis patients with strong efficacy and safety data;
  • Continued promising pre-clinical work for ATB-346 in experimental
  • Launched Neomem® FlexPlus, a high-performance barrier membrane for
    regenerative procedures in oral surgery;
  • Appointed Yung Wu, Managing Director of private equity firm NFQ
    Ventures and a seasoned entrepreneur, to the Board of Directors; and
  • Presented at the 2016 Rodman Renshaw Global Investment Conference.

Post Q2 2017 Highlights

  • Initiated strategic growth initiative for Citagenix in the United
    States, the largest global market for dental biologics; and
  • Confirmed non-addictive properties for Antibe’s second pipeline drug,
    ATB-352, a potent pain-killer.

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation. Antibe’s
technology involves linking a hydrogen sulfide-releasing molecule to an
existing drug to produce a patented, improved medicine. Antibe’s lead
drug ATB-346 targets the global need for a safer drug for chronic pain
and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets
the urgent global need for a safer, non-addictive analgesic for treating
severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.

Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the
sales and marketing of tissue regenerative products servicing the
orthopedic and dental marketplaces. Since its inception in 1997,
Citagenix has become the largest source of knowledge and experience in
the Canadian medical device industry. Citagenix Inc. is active in 15
countries, operating in Canada through its direct sales teams, and
internationally via a network of distributor partnerships.

Forward Looking Information

This news release includes certain forward-looking statements, which may
include, but are not limited to, the growth of product sales, engaging
new distributors and independent representatives and the licensing and
development of drugs and medical devices. Any statements contained
herein that are not statements of historical facts may be deemed to be
forward-looking, including those identified by the expressions “will”,
“anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”,
“propose” and similar expressions. Forward-looking statements involve
known and unknown risks and uncertainties that could cause actual
results, performance, or achievements to differ materially from those
expressed or implied in this news release. Factors that could cause
actual results to differ materially from those anticipated in this news
release include, but are not limited to, the Company’s ability to secure
additional financing, its ability to execute its business strategy and
successfully compete in the market, and risks associated with drug and
medical device development generally. Antibe Therapeutics Inc. assumes
no obligation to update the forward-looking statements or to update the
reasons why actual results could differ from those reflected in the
forward-looking statements except as required by applicable law.

Copyright © 2016 Businesswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Leave a Reply